Company: EVGN
Filing Date: 2025-03-27
Form Type: 20-F
Source: 0001178913-25-001092
Chunk: 106

Company: Evogene Ltd.
Filing Date: 2025-03-27
Form: 20-F
Item: Item 4A
Chunk 106
---
 sell or the dates on which any such sales will take place.

Cantor Controlled Equity OfferingSMSales
Agreement

On January 14, 2021 and February 19, 2021, we entered into Controlled
Equity OfferingSMSales Agreements, or the January
Sales Agreement and February Sales Agreement, respectively, with Cantor Fitzgerald & Co., or the Agent, pursuant to which the Company
could offer and sell, from time to time, its ordinary shares, through the Agent in an “at-the-market”, or ATM offering, as
defined in Rule 415(a)(4) promulgated under the Securities Act, for an aggregate offering price of up to $28.0 million and $50.0 million,
respectively. In February 2021, we completed the sales of ordinary shares under the January Sales Agreement and issued 380,359 ordinary
shares, with a weighted average selling price of $73.61 per share, resulting in gross proceeds of approximately $28 million. Subsequently
we entered into the February Sales Agreement, which was subsequently reduced to approximately $19.5 million. As of December 31, 2023,
we sold 147,556 ordinary shares with a weighted average selling price of $22.76 per share, resulting in gross proceeds of approximately
$3.36 million. In March 2024, we terminated this ATM offering; prior to termination we had sold 147,876 ordinary shares with a weighted
average selling price of $22.73 per share, resulting in gross proceeds of approximately $3.36 million.

Shelf Registration Statement

We have an effective registration statement that registered up
to $200 million of our ordinary shares, debt securities, rights, warrants and units. Because the public float of our ordinary shares is
currently less than $75.0 million, we are limited in the amount we can raise during any 12-month period to 1/3 of our public float on
the date of sale, which was approximately $3.97 million as of March 19, 2025. This amount may vary according to changes in our share price.
We may seek additional capital or strategic considerations, even if we believe we have sufficient funds for our current or future operating
plans. Following the effectiveness of our new shelf registration statement, we entered into a new sales agreement with Lake Street, as
described above.

67

2023 Registered Direct Offering

On July 17, 2023, we entered into a